OpGen (OPGN) Competitors $0.77 -0.22 (-22.07%) As of 02:33 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsTrends OPGN vs. ENZ, CCM, MRAI, KDLY, MGRX, BRTX, SSY, VSEE, OTRK, and DHACShould you be buying OpGen stock or one of its competitors? The main competitors of OpGen include Enzo Biochem (ENZ), Concord Medical Services (CCM), Marpai (MRAI), Kindly MD (KDLY), Mangoceuticals (MGRX), BioRestorative Therapies (BRTX), SunLink Health Systems (SSY), Vsee Health (VSEE), Ontrak (OTRK), and Digital Health Acquisition (DHAC). These companies are all part of the "healthcare" industry. OpGen vs. Enzo Biochem Concord Medical Services Marpai Kindly MD Mangoceuticals BioRestorative Therapies SunLink Health Systems Vsee Health Ontrak Digital Health Acquisition Enzo Biochem (NYSE:ENZ) and OpGen (NASDAQ:OPGN) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, valuation, community ranking, analyst recommendations, earnings, institutional ownership, risk, dividends and media sentiment. Does the MarketBeat Community prefer ENZ or OPGN? OpGen received 89 more outperform votes than Enzo Biochem when rated by MarketBeat users. However, 53.54% of users gave Enzo Biochem an outperform vote while only 52.71% of users gave OpGen an outperform vote. CompanyUnderperformOutperformEnzo BiochemOutperform Votes21253.54% Underperform Votes18446.46% OpGenOutperform Votes30152.71% Underperform Votes27047.29% Which has more volatility & risk, ENZ or OPGN? Enzo Biochem has a beta of 0.81, meaning that its share price is 19% less volatile than the S&P 500. Comparatively, OpGen has a beta of 0.34, meaning that its share price is 66% less volatile than the S&P 500. Which has better valuation and earnings, ENZ or OPGN? Enzo Biochem has higher revenue and earnings than OpGen. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEnzo Biochem$30.31M0.80-$26.08MN/AN/AOpGen$2.67M2.39-$32.67MN/AN/A Do insiders and institutionals have more ownership in ENZ or OPGN? 36.9% of Enzo Biochem shares are held by institutional investors. Comparatively, 2.7% of OpGen shares are held by institutional investors. 11.4% of Enzo Biochem shares are held by insiders. Comparatively, 43.8% of OpGen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Is ENZ or OPGN more profitable? Enzo Biochem has a net margin of -75.34% compared to OpGen's net margin of -1,140.36%. OpGen's return on equity of 0.00% beat Enzo Biochem's return on equity.Company Net Margins Return on Equity Return on Assets Enzo Biochem-75.34% -7.96% -5.49% OpGen -1,140.36%N/A -287.58% Does the media refer more to ENZ or OPGN? In the previous week, OpGen had 1 more articles in the media than Enzo Biochem. MarketBeat recorded 1 mentions for OpGen and 0 mentions for Enzo Biochem. Enzo Biochem's average media sentiment score of 0.00 equaled OpGen'saverage media sentiment score. Company Overall Sentiment Enzo Biochem Neutral OpGen Neutral SummaryEnzo Biochem beats OpGen on 7 of the 12 factors compared between the two stocks. Get OpGen News Delivered to You Automatically Sign up to receive the latest news and ratings for OPGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OPGN vs. The Competition Export to ExcelMetricOpGenMedical laboratories IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.39M$3.00B$5.82B$8.44BDividend YieldN/A21.56%4.76%3.97%P/E RatioN/A14.4224.9719.23Price / Sales2.39200.75375.65113.16Price / CashN/A57.5638.0534.62Price / Book-0.074.477.304.29Net Income-$32.67M-$22.21M$3.19B$246.62M7 Day Performance-27.13%-2.25%-2.95%-3.40%1 Month Performance-18.91%-12.31%-6.85%-6.57%1 Year Performance-87.03%-5.31%12.37%4.18% OpGen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OPGNOpGenN/A$0.77-22.1%N/A-83.2%$6.39M$2.67M0.00100Analyst ForecastNews CoverageGap DownENZEnzo Biochem0.7774 of 5 stars$0.50-2.8%N/A-62.8%$26.23M$30.31M0.00520Upcoming EarningsCCMConcord Medical Services1.3469 of 5 stars$4.84+5.2%N/A-3.4%$21.02M$471.70M0.00970Short Interest ↓News CoverageMRAIMarpai1.587 of 5 stars$1.02+6.5%$6.00+488.2%-40.6%$14.77M$37.15M-0.39150KDLYKindly MDN/A$2.11-10.6%N/AN/A$12.62MN/A0.00N/AMGRXMangoceuticals0.4119 of 5 stars$4.60+6.2%N/A-92.6%$11.45M$730,000.00-0.793Short Interest ↑BRTXBioRestorative Therapies3.8566 of 5 stars$1.60-11.1%$18.00+1,025.0%+0.7%$11.07M$377,000.00-1.057SSYSunLink Health SystemsN/A$0.990.0%N/A+30.2%$6.97M$32.44M7.071,376Analyst ForecastVSEEVsee Health1.923 of 5 stars$1.83+0.5%$5.00+173.2%N/A$6.59MN/A0.00N/AShort Interest ↓Gap UpOTRKOntrak3.0618 of 5 stars$1.56-2.0%$45.00+2,784.6%-40.2%$6.58M$12.74M-0.15250Positive NewsDHACDigital Health AcquisitionN/A$1.82-5.7%N/A-87.1%$6.56MN/A0.002,021 Related Companies and Tools Related Companies ENZ Competitors CCM Competitors MRAI Competitors KDLY Competitors MGRX Competitors BRTX Competitors SSY Competitors VSEE Competitors OTRK Competitors DHAC Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:OPGN) was last updated on 3/4/2025 by MarketBeat.com Staff From Our PartnersURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | Sponsored77 Hedge Funds Are Betting On This Off-Radar MineralWith surging prices... supply shortages... and growing demand, hedge funds are betting big on potash. In fa...The Tomorrow Investor | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | SponsoredWhy 2026 will be a disaster for many AmericansWall Street Legend: Why stocks are very likely to crash in Trump's 2nd Year Legendary investor Marc Chaikin...Chaikin Analytics | SponsoredTexas approves new currencyRural Texas Town Ramps Up Global Currency War A small town has joined a radical $1.9 trillion attack on the...Stansberry Research | SponsoredBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OpGen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share OpGen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
